RxDoctor Payments Data

Mitchell Halter, MD

Pain Medicine · Tucson, AZNPI 1841287398

Payments from drug & device makers

$4,893in general payments, 2019–2025

Across 186 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$655
  • Lilly USA, LLC$407
  • Novartis$381
  • Biohaven Pharmaceuticals, Inc.$365
  • Lundbeck LLC$328
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,885100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,893 in reported general payments places this provider in the 55th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$177,523
Medicare patients
264
Services billed
12,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina24$38,315
QuliptaAtogepant12$15,261
Ajovy AutoinjectorFremanezumab-Vfrm13$9,588
Baclofen241$5,867
Famciclovir11$2,662
Oxcarbazepine14$1,907
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$1,329
Doxepin Hcl32$1,324
Pregabalin27$1,008
Gabapentin23$628
Tizanidine Hcl29$610
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine14$408
Amitriptyline Hcl19$376
Duloxetine Hcl14$369
Clonazepam18$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta$1,661$53,57636 claims
Upsher-smith Laboratories LLCTopiramate$74$30335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →